---
title: "Pre-existing Multidimensional Immune Signature Predicts Omicron Infection Risk in Vaccinated Indiv"
id: "medrxiv-0-a-multidimensional-immune-signature-predicts-susceptibility-to-omicron"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-a-multidimensional-immune-signature-predicts-susceptibility-to-omicron"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pre-existing Multidimensional Immune Signature Predicts Omicron Infection Risk in Vaccinated Indiv
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-a-multidimensional-immune-signature-predicts-susceptibility-to-omicron
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This observational study compared vaccinated individuals who remained uninfected with those who became infected during the first **Omicron** wave, using blood samples collected at baseline and 24 weeks later. - Researchers measured innate and adaptive responses using isolated peripheral blood mononuclear cells (PBMCs) and polymorphonuclear neutrophils (PMNs). Innate stimulation used the TLR7/8 agonist R848; adaptive assays used SARS-CoV-2 peptide pools and highly purified inactivated viruses (ancestral and **Omicron BA.1**). - Prior to infection, the group that later became infected showed reduced **CD4** and **CD8 T-cell proliferative responses** to antigenic stimulation despite having largely similar immune cell phenotypes compared with the uninfected group, indicating a pre-existing functional deficit. - The same susceptible group exhibited broadly increased **TNF** production across stimulation conditions before infection, consistent with a heightened inflammatory profile. - After infection, some T-cell functions improved: proliferation and **IFN-gamma** production partially recovered in response to viral antigens, but responses specifically to Omicron BA.1 remained suboptimal. - The infected group also displayed greater inflammatory activity overall, including increased TNF and IFN-gamma production, higher anti-nucleocapsid IgG3 levels, increased frequencies of B cells and myeloid cells, lower circulating interferon-inducible T-cell Alpha Chemoattractant (I-TAC), and a modest reduction in PMN IL-8 responses. - Many of these immunologic alterations were detectable before infection and persisted afterward, supporting their role as determinants of susceptibility rather than consequences of infection. - Beyond magnitude differences, protection correlated with functional coordination within the humoral compartment: the relationship between **Spike-binding antibodies** and neutralizing activity differed between protected and susceptible individuals. - Overall, the findings indicate that susceptibility to Omicron infection is associated with a pre-existing, persistent, multidimensional immune imbalance affecting both innate and adaptive arms of immunity. - The study is a preprint and has not been peer-reviewed; institutional ethics approval and participant informed consent were obtained as reported by the authors.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=rt5AE74fyEwpihmLXOI0fpCXOsJzWQ9j2YDulNW2DqY-1788581678.2293537-1.2.1.1-T1fORpoi3hg62ftAYO4TH9HuZ0anMa6iQjA_utYe4J67YI51UxTT_xtCQPRnSPnm) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # A Multidimensional Immune Signature Predicts Susceptibility to Omicron Infection in Vaccinated Individuals Hend Jarras, [ View ORCID Profile](http://orcid.org/0000-0002-7660-9280)Wilfried Wenceslas Bazie, Isalie Blais, Benjamin Goyer, Julien Boucher, Arielle Pakenham, Kimberly Dancause-Caron, Henintsoa Rabezanahary, [ View ORCID Profile](http://orcid.org/0000-0002-7293-7623)Mathieu Theriault, Kim Santerre, [ View ORCID Profile](http://orcid.org/0000-0003-4652-3029)Marc-Andre Langlois, [ View ORCID Profile](http://orcid.org/0000-0001-7177-7763)Philippe A Tessier, [ View ORCID Profile](http://orcid.org/0000-0002-0101-0468)Jean-Francois Masson, [ View ORCID Profile](http://orcid.org/0000-0002-2934-6940)Joelle N Pelletier, [ View ORCID Profile](http://orcid.org/0000-0001-6042-3177)Nicholas Brousseau, [ View ORCID Profile](http://orcid.org/0000-0001-5152-2464)Denis Boudreau, [ View ORCID Profile](http://orcid.org/0000-0002-3986-5146)Sylvie Trottier, [ View ORCID Profile](http://orcid.org/0000-0002-1230-0735)Mariana Baz, [ View ORCID Profile](http://orcid.org/0000-0003-2722-1180)Caroline Gilbert doi: https://doi.org/10.64898/2026.08.31.26361844 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Hend Jarras 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hend%2BJarras%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jarras%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHend%2BJarras%2B) Wilfried Wenceslas Bazie 2 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada, Programme de Recherche sur les Maladies Infectieuses, Centre Muraz, Institut National de Sante Publique, Bobo-Dioulasso, Houet, Burkina F; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wilfried%2BWenceslas%2BBazie%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bazie%20WW&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWilfried%2BWenceslas%2BBazie%2B) * [ORCID record for Wilfried Wenceslas Bazie](http://orcid.org/0000-0002-7660-9280 "Open in new tab") Isalie Blais 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Isalie%2BBlais%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Blais%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIsalie%2BBlais%2B) Benjamin Goyer 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2BGoyer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Goyer%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2BGoyer%2B) Julien Boucher 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Julien%2BBoucher%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Boucher%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJulien%2BBoucher%2B) Arielle Pakenham 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Arielle%2BPakenham%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pakenham%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AArielle%2BPakenham%2B) Kimberly Dancause-Caron 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kimberly%2BDancause-Caron%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dancause-Caron%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKimberly%2BDancause-Caron%2B) Henintsoa Rabezanahary 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Henintsoa%2BRabezanahary%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rabezanahary%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHenintsoa%2BRabezanahary%2B) Mathieu Theriault 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mathieu%2BTheriault%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Theriault%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMathieu%2BTheriault%2B) * [ORCID record for Mathieu Theriault](http://orcid.org/0000-0002-7293-7623 "Open in new tab") Kim Santerre 1 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kim%2BSanterre%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Santerre%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKim%2BSanterre%2B) Marc-Andre Langlois 3 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marc-Andre%2BLanglois%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Langlois%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarc-Andre%2BLanglois%2B) * [ORCID record for Marc-Andre Langlois](http://orcid.org/0000-0003-4652-3029 "Open in new tab") Philippe A Tessier 4 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada, Departement de Microbiologie-Infectiologie et d Immunologie, Faculte de Medecine, Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Philippe%2BA%2BTessier%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tessier%20PA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APhilippe%2BA%2BTessier%2B) * [ORCID record for Philippe A Tessier](http://orcid.org/0000-0001-7177-7763 "Open in new tab") Jean-Francois Masson 5 Department of Chemistry, Institut Courtois, Quebec Center for Advanced Materials, Regroupement quebecois sur les materiaux de pointe, and Centre interdisciplinaire de recherche sur le cerveau et l apprentissage, Universite de Montreal, Montreal, QC, Canad; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jean-Francois%2BMasson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Masson%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJean-Francois%2BMasson%2B) * [ORCID record for Jean-Francois Masson](http://orcid.org/0000-0002-0101-0468 "Open in new tab") Joelle N Pelletier 6 Department of Chemistry, Department of Biochemistry, Universite de Montreal, Montreal, QC, Canada, PROTEO- The Quebec Network for Research on Protein Function, Engineering, and Applications, Quebec City, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joelle%2BN%2BPelletier%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pelletier%20JN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoelle%2BN%2BPelletier%2B) * [ORCID record for Joelle N Pelletier](http://orcid.org/0000-0002-2934-6940 "Open in new tab") Nicholas Brousseau 7 Direction des risques biologiques, Institut national de sante publique du Quebec, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nicholas%2BBrousseau%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brousseau%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANicholas%2BBrousseau%2B) * [ORCID record for Nicholas Brousseau](http://orcid.org/0000-0001-6042-3177 "Open in new tab") Denis Boudreau 8 Departement de chimie et Centre d optique, photonique et laser COPL, Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Denis%2BBoudreau%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Boudreau%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADenis%2BBoudreau%2B) * [ORCID record for Denis Boudreau](http://orcid.org/0000-0001-5152-2464 "Open in new tab") Sylvie Trottier 9 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada, Centre de recherche en infectiologie de l Universite Laval, Quebec, QC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sylvie%2BTrottier%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Trottier%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASylvie%2BTrottier%2B) * [ORCID record for Sylvie Trottier](http://orcid.org/0000-0002-3986-5146 "Open in new tab") Mariana Baz 10 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada, Departement de Microbiologie-Infectiologie et d Immunologie, Faculte de Medecine, Universite Laval, Quebec, QC, Canada, Centre de recherc * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mariana%2BBaz%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Baz%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMariana%2BBaz%2B) * [ORCID record for Mariana Baz](http://orcid.org/0000-0002-1230-0735 "Open in new tab") Caroline Gilbert 10 Axe Maladies infectieuses et immunitaires, Centre de recherche du CHU de Quebec-Universite Laval, Quebec, QC, Canada, Departement de Microbiologie-Infectiologie et d Immunologie, Faculte de Medecine, Universite Laval, Quebec, QC, Canada, Centre de recherc * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Caroline%2BGilbert%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gilbert%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACaroline%2BGilbert%2B) * [ORCID record for Caroline Gilbert](http://orcid.org/0000-0003-2722-1180 "Open in new tab") * For correspondence: caroline.gilbert@crchudequebec.ulaval.ca * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1293020/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1293020/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1293020/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1293020/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1293020/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.31.26361844v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1293020/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Substantial inter-individual variation in susceptibility to viral infection persists despite widespread vaccination, and its immunological basis remains poorly understood. We investigated how innate and adaptive immune responses contribute to susceptibility to SARS-CoV-2 infection during the early COVID-19 pandemic. We compared two groups of vaccinated individuals who either remained uninfected or became infected during the first Omicron wave. Blood samples were collected at baseline and 24 weeks later. Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear neutrophils (PMNs) were isolated and stimulated with the TLR7/8 agonist R848 to assess innate responses. PBMCs were stimulated with SARS-CoV-2 peptide pools and highly purified inactivated viruses (ancestral and Omicron BA.1) to evaluate adaptive immunity. Prior to infection, individuals in the infected group exhibited reduced CD4 and CD8 T cells proliferative responses, alongside with increased TNF production across all stimulation conditions, despite largely comparable immune phenotypes, indicating a pre-existing functional immune deficit. Following infection, T-cell proliferation and IFN-gamma production were partially restored in response to viral antigens, although responses to Omicron BA.1 remained suboptimal. This functional deficit was accompanied by heightened inflammatory activity, including increased TNF and IFN-gamma production, elevated anti-nucleocapsid IgG3 levels, higher frequencies of B cells and myeloid cells, reduced circulating interferon-inducible T-cell Alpha Chemoattractant (I-TAC) concentrations, and a modest impairment in PMN IL-8 responses. Notably, these alterations were detectable prior to infection and persisted thereafter, indicating that they represent determinants rather than consequences of viral infection. Importantly, beyond differences in the magnitude of immune responses, protection was associated with the degree of functional coordination within the humoral compartment, as reflected by the relationship between Spike-binding antibodies and neutralizing activity. Together, these results demonstrate that susceptibility to Omicron infection is linked to a pre-existing and persistent functional immune imbalance affecting both innate and adaptive arms of immunity. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Centre de Recherche du CHU de Quebec-Universite Laval (Quebec, QC, Canada) ethics review boards (CER- 2021-5744) and conducted according to the guidelines of the Declaration of Helsinki. All participants provided written informed consent prior to enrollment. All experiments with SARS-CoV-2 and participant samples were performed in the Containment Level 2 and 3 (CL2, CL3) laboratories at the CHU de Quebec-Universite Laval. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported i
## Related Clinical Research

- [WHO validates Bhutan for eliminating dog-transmitted human rabies](https://medichelpline.com/clinical-feed/who-0-0-who-validates-bhutan-for-eliminating-dog-transmitted-human-rabies.md)
- [Infection prevention and control implementation during COVID-19 in sub-Saharan Africa: multination](https://medichelpline.com/clinical-feed/bmj-open-0-infection-prevention-and-control-measures-during-the-covid-19-pandemic-in-sub.md)
- [Hepatitis C Prevalence and Care Barriers in Adults with Serious Mental Illness: Updated Systematic](https://medichelpline.com/clinical-feed/bmj-open-6-pooled-prevalence-risk-factors-and-barriers-to-care-for-hepatitis-c-virus-hcv.md)
- [WHO validates Timor-Leste’s elimination of trachoma as a public health problem](https://medichelpline.com/clinical-feed/who-0-0-who-validates-timor-leste-s-elimination-of-trachoma-as-a-public-health-problem.md)
- [Fauci on pandemic memory: selective amnesia and its effect on views of masking and lockdowns](https://medichelpline.com/clinical-feed/stat-news-1-stat-fauci-speaks-and-writes.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.